141 related articles for article (PubMed ID: 17764508)
1. In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn.
Nielsen LK; Green TH; Sandlie I; Michaelsen TE; Dziegiel MH
Transfusion; 2008 Jan; 48(1):12-9. PubMed ID: 17764508
[TBL] [Abstract][Full Text] [Related]
2. Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D.
Nielsen LK; Green TH; Norderhaug L; Sandlie I; Dziegiel MH
Transfusion; 2007 Feb; 47(2):306-15. PubMed ID: 17302778
[TBL] [Abstract][Full Text] [Related]
3. In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells.
Nielsen LK; Norderhaug L; Sandlie I; Dziegiel MH
APMIS; 2006 May; 114(5):345-51. PubMed ID: 16725010
[TBL] [Abstract][Full Text] [Related]
4. [Immunoglobulin G monoclonal human anti-rhesus Rho(D) to prevent rhesus-incompatibility].
Olovnikova NI; Belkina EV; Drize NI; Konopliannikov AG; Lemeneva LN; Miterev GIu; Nikolaeva TL; Savel'eva GM; Chertkov IL
Klin Med (Mosk); 1997; 75(7):39-43. PubMed ID: 9411052
[TBL] [Abstract][Full Text] [Related]
5. Immunologic basis and immunoprophylaxis of RhD induced hemolytic disease of the newborn (HDN).
Payam Khaja Pasha R; Shokri F
Iran J Immunol; 2008 Dec; 5(4):189-200. PubMed ID: 19098362
[TBL] [Abstract][Full Text] [Related]
6. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M
Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570
[TBL] [Abstract][Full Text] [Related]
7. Differences between the activities of human monoclonal IgG1 and IgG3 anti-D antibodies of the Rh blood group system in their abilities to mediate effector functions of monocytes.
Wiener E; Jolliffe VM; Scott HC; Kumpel BM; Thompson KM; Melamed MD; Hughes-Jones NC
Immunology; 1988 Oct; 65(2):159-63. PubMed ID: 3192267
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?
Brinc D; Denomme GA; Lazarus AH
Curr Opin Hematol; 2009 Nov; 16(6):488-96. PubMed ID: 19730101
[TBL] [Abstract][Full Text] [Related]
9. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies.
Beliard R; Waegemans T; Notelet D; Massad L; Dhainaut F; Romeuf Cd; Guemas E; Haazen W; Bourel D; Teillaud JL; Prost JF
Br J Haematol; 2008 Apr; 141(1):109-19. PubMed ID: 18279459
[TBL] [Abstract][Full Text] [Related]
10. Antibody dependent cell mediated cytotoxicity and erythrophagocytosis assays in Rh haemolytic disease of the newborn.
Patil JS; Gupte SC
Ceylon Med J; 1996 Jun; 41(2):46-50. PubMed ID: 8771942
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma treated monocyte/macrophage phagocytosis of red cells sensitized with IgG1 and IgG3 Anti-D containing identical immunoglobulin variable region genes.
Perri D; Shabani F; Ziaeian G; Denomme GA
Transfus Apher Sci; 2008 Aug; 39(1):37-44. PubMed ID: 18614400
[TBL] [Abstract][Full Text] [Related]
12. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
Kumpel BM
Vox Sang; 2007 Aug; 93(2):99-111. PubMed ID: 17683353
[TBL] [Abstract][Full Text] [Related]
14. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity.
Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M
Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506
[TBL] [Abstract][Full Text] [Related]
15. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
[TBL] [Abstract][Full Text] [Related]
16. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
[TBL] [Abstract][Full Text] [Related]
17. Production of target-specific recombinant human polyclonal antibodies in mammalian cells.
Wiberg FC; Rasmussen SK; Frandsen TP; Rasmussen LK; Tengbjerg K; Coljee VW; Sharon J; Yang CY; Bregenholt S; Nielsen LS; Haurum JS; Tolstrup AB
Biotechnol Bioeng; 2006 Jun; 94(2):396-405. PubMed ID: 16596663
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
19. Fatal hemolytic disease of the fetus and newborn associated with anti-Jr.
Peyrard T; Pham BN; Arnaud L; Fleutiaux S; Brossard Y; Guerin B; Desmoulins I; Rouger P; Le Pennec PY
Transfusion; 2008 Sep; 48(9):1906-11. PubMed ID: 18522708
[TBL] [Abstract][Full Text] [Related]
20. Anti-D and anti-i activities are inseparable in V4-34-encoded monoclonal anti-D: the same framework 1 residues are required for both reactivities.
Thorpe SJ; Ball C; Fox B; Thompson KM; Thorpe R; Bristow A
Transfusion; 2008 May; 48(5):930-40. PubMed ID: 18346025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
